EGFR and lung carcinoma: Specifically, this new model uses detailed pharmacokinetic data to examine three possible clinical scenarios involving EGFR mutant lung cancer treated with erlotinib: mutation rates are independent of treatment, increase with treatment, or decrease with treatment.